Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes

Stem Cell Reports

Volumn 7, Issue 3, 2016, Pages 355-369

  Josowitz, Rebecca ^a   Mulero Navarro, Sonia ^a   Rodriguez, Nelson A ^a   Falce, Christine ^a   Cohen, Ninette ^a   Ullian, Erik M ^b,c   Weiss, Lauren A ^c   Rauen, Katherine A ^d   Sobie, Eric A ^a   Gelb, Bruce D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; B RAF KINASE; B RAF KINASE 1; B RAF KINASE 2; B RAF KINASE 3; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; KRUPPEL LIKE FACTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOLAMBAN; RAS PROTEIN; SIRP ALPHA; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CELL INTERACTION; CELL SELECTION; CYTOKINE RELEASE; FETUS; GENE EXPRESSION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; INDUCED PLURIPOTENT STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL DIFFERENTIATION; CELL SEPARATION; CYTOLOGY; GENETICS; METABOLISM; MUTATION; NUCLEAR REPROGRAMMING; PARACRINE SIGNALING; PATHOLOGY;

BIOMARKERS; CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC; CELL DIFFERENTIATION; CELL SEPARATION; CELLULAR REPROGRAMMING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84990036865     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2016.07.018     Document Type: Article

References (50)

1. Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., Liu, D., MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol., 6, 2013, 27.
2. Andreadi, C., Cheung, L.K., Giblett, S., Patel, B., Jin, H., Mercer, K., Kamata, T., Lee, P., Williams, A., McMahon, M., et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev. 26 (2012), 1945–1958.
3. Aoki, H., Sadoshima, J., Izumo, S., Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro. Nat. Med. 6 (2000), 183–188.
4. Araujo, A.Q., Arteaga, E., Ianni, B.M., Buck, P.C., Rabello, R., Mady, C., Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 96 (2005), 1563–1567.
5. Armour, C.M., Allanson, J.E., Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J. Med. Genet. 45 (2008), 249–254.
6. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ. Res. 83 (1998), 1205–1214.
7. Bouzegrhane, F., Thibault, G., Is angiotensin II a proliferative factor of cardiac fibroblasts?. Cardiovasc. Res. 53 (2002), 304–312.
8. Bueno, O.F., De Windt, L.J., Tymitz, K.M., Witt, S.A., Kimball, T.R., Klevitsky, R., Hewett, T.E., Jones, S.P., Lefer, D.J., Peng, C.F., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19 (2000), 6341–6350.
9. Camelliti, P., Borg, T.K., Kohl, P., Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65 (2005), 40–51.
10. Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., Ang, Y.S., Schaniel, C., Lee, D.F., Yang, L., Kaplan, A.D., Adler, E.D., Rozov, R., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465 (2010), 808–812.
11. Cashman, T.J., Josowitz, R., Johnson, B.V., Gelb, B.D., Costa, K.D., Human engineered cardiac tissues created using induced pluripotent stem cells reveal functional characteristics of BRAF-mediated hypertrophic cardiomyopathy. PLoS One, 11, 2016, e0146697.
12. 2+ fluxes, and sarcoplasmic reticulum loading in pressure-overload hypertrophy. Am. J. Physiol. 272 (1997), H2425–H2435.
13. Dubois, N.C., Craft, A.M., Sharma, P., Elliott, D.A., Stanley, E.G., Elefanty, A.G., Gramolini, A., Keller, G., SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 29 (2011), 1011–1018.
14. Fredj, S., Bescond, J., Louault, C., Potreau, D., Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J. Cell Physiol. 202 (2005), 891–899.
15. Fujiu, K., Nagai, R., Fibroblast-mediated pathways in cardiac hypertrophy. J. Mol. Cell Cardiol. 70C (2014), 64–73.
16. Gray, M.O., Long, C.S., Kalinyak, J.E., Li, H.T., Karliner, J.S., Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 40 (1998), 352–363.
17. Harris, I.S., Zhang, S., Treskov, I., Kovacs, A., Weinheimer, C., Muslin, A.J., Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 (2004), 718–723.
18. Harris, K.M., Spirito, P., Maron, M.S., Zenovich, A.G., Formisano, F., Lesser, J.R., Mackey-Bojack, S., Manning, W.J., Udelson, J.E., Maron, B.J., Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114 (2006), 216–225.
19. Heineke, J., Molkentin, J.D., Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7 (2006), 589–600.
20. Herrera-Molina, R., Valdivia, A., Kong, M., Alvarez, A., Cardenas, A., Quest, A.F., Leyton, L., Thy-1-interacting molecules and cellular signaling in cis and trans. Int. Rev. Cell Mol. Biol. 305 (2013), 163–216.
21. Hunter, J.J., Tanaka, N., Rockman, H.A., Ross, J. Jr., Chien, K.R., Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270 (1995), 23173–23178.
22. Kawano, H., Do, Y.S., Kawano, Y., Starnes, V., Barr, M., Law, R.E., Hsueh, W.A., Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101 (2000), 1130–1137.
23. Kisselbach, L., Merges, M., Bossie, A., Boyd, A., CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. Cytotechnology 59 (2009), 31–44.
24. Koitabashi, N., Danner, T., Zaiman, A.L., Pinto, Y.M., Rowell, J., Mankowski, J., Zhang, D., Nakamura, T., Takimoto, E., Kass, D.A., Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121 (2011), 2301–2312.
25. Konno, T., Chang, S., Seidman, J.G., Seidman, C.E., Genetics of hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 25 (2010), 205–209.
26. Kuwahara, F., Kai, H., Tokuda, K., Kai, M., Takeshita, A., Egashira, K., Imaizumi, T., Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002), 130–135.
27. Kuwahara, K., Saito, Y., Takano, M., Arai, Y., Yasuno, S., Nakagawa, Y., Takahashi, N., Adachi, Y., Takemura, G., Horie, M., et al. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J. 22 (2003), 6310–6321.
28. Lan, F., Lee, A.S., Liang, P., Sanchez-Freire, V., Nguyen, P.K., Wang, L., Han, L., Yen, M., Wang, Y., Sun, N., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12 (2013), 101–113.
29. Lim, D.S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., Marian, A.J., Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001), 789–791.
30. Lundy, S.D., Zhu, W.Z., Regnier, M., Laflamme, M.A., Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 22 (2013), 1991–2002.
31. Marin, T.M., Keith, K., Davies, B., Conner, D.A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121 (2011), 1026–1043.
32. Molkentin, J.D., Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 63 (2004), 467–475.
33. Mummery, C.L., Zhang, J., Ng, E.S., Elliott, D.A., Elefanty, A.G., Kamp, T.J., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 111 (2012), 344–358.
34. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8 (2011), 409–412.
35. Purcell, N.H., Wilkins, B.J., York, A., Saba-El-Leil, M.K., Meloche, S., Robbins, J., Molkentin, J.D., Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 104 (2007), 14074–14079.
36. Rodriguez-Viciana, P., Tetsu, O., Tidyman, W.E., Estep, A.L., Conger, B.A., Cruz, M.S., McCormick, F., Rauen, K.A., Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006), 1287–1290.
37. Schultz Jel, J., Witt, S.A., Glascock, B.J., Nieman, M.L., Reiser, P.J., Nix, S.L., Kimball, T.R., Doetschman, T., TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest. 109 (2002), 787–796.
38. Shimada, Y.J., Passeri, J.J., Baggish, A.L., O'Callaghan, C., Lowry, P.A., Yannekis, G., Abbara, S., Ghoshhajra, B.B., Rothman, R.D., Ho, C.Y., et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 1 (2013), 480–487.
39. Sipido, K.R., Volders, P.G., de Groot, S.H., Verdonck, F., Van de Werf, F., Wellens, H.J., Vos, M.A., Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 102 (2000), 2137–2144.
40. Tartaglia, M., Gelb, B.D., Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann. N. Y. Acad. Sci. 1214 (2010), 99–121.
41. Teekakirikul, P., Eminaga, S., Toka, O., Alcalai, R., Wang, L., Wakimoto, H., Nayor, M., Konno, T., Gorham, J.M., Wolf, C.M., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-beta. J. Clin. Invest. 120 (2010), 3520–3529.
42. Toivonen, S., Ojala, M., Hyysalo, A., Ilmarinen, T., Rajala, K., Pekkanen-Mattila, M., Aanismaa, R., Lundin, K., Palgi, J., Weltner, J., et al. Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. Stem Cells Transl. Med. 2 (2013), 83–93.
43. Urosevic, J., Sauzeau, V., Soto-Montenegro, M.L., Reig, S., Desco, M., Wright, E.M., Canamero, M., Mulero, F., Ortega, S., Bustelo, X.R., et al. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc. Natl. Acad. Sci. USA 108 (2011), 5015–5020.
44. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004), 855–867.
45. Wu, X., Simpson, J., Hong, J.H., Kim, K.H., Thavarajah, N.K., Backx, P.H., Neel, B.G., Araki, T., MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J. Clin. Invest. 121 (2011), 1009–1025.
46. Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453 (2008), 524–528.
47. Yang, X., Pabon, L., Murry, C.E., Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 114 (2014), 511–523.
48. Yoon, G., Rosenberg, J., Blaser, S., Rauen, K.A., Neurological complications of cardio-facio-cutaneous syndrome. Dev. Med. Child Neurol. 49 (2007), 894–899.
49. Zanella, F., Lyon, R.C., Sheikh, F., Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes. Trends Cardiovasc. Med. 24 (2014), 32–44.
50. Zheng, M., Dilly, K., Dos Santos Cruz, J., Li, M., Gu, Y., Ursitti, J.A., Chen, J., Ross, J. Jr., Chien, K.R., Lederer, J.W., et al. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am. J. Physiol. Heart Circ. Physiol. 286 (2004), H424–H433.